These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35577632)

  • 1. Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Kumar Suri R; Hayman B; Prasad SD; Makhoana M; Tippoo P
    Vaccine; 2022 Jun; 40(26):3495-3505. PubMed ID: 35577632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
    Pagliusi S; Hayman B; Jarrett S
    Vaccine; 2021 Apr; 39(18):2479-2488. PubMed ID: 33838948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.
    Pagliusi S; Makhoana M; Datla M; Leite L; Hendriks J; Gholami A; Huang W; Gao Y; Jadhav S; Harshavardhan GV; Wu Y; Suhardono M; Homma A
    Vaccine; 2013 Jun; 31(31):3111-5. PubMed ID: 23684836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors, enablers and challenges for COVID-19 vaccine development.
    Excler JL; Saville M; Privor-Dumm L; Gilbert S; Hotez PJ; Thompson D; Abdool-Karim S; Kim JH
    BMJ Glob Health; 2023 Jun; 8(6):. PubMed ID: 37277195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustainable vaccine manufacturing in low- and middle-Income countries.
    Hayman B; Kumar Suri R; Downham M
    Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
    Kana BD; Arbuthnot P; Botwe BK; Choonara YE; Hassan F; Louzir H; Matsoso P; Moore PL; Muhairwe A; Naidoo K; Ndomondo-Sigonda M; Madhi SA
    Lancet Infect Dis; 2023 Aug; 23(8):e288-e300. PubMed ID: 37290473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines, inspiring innovation in health.
    Pagliusi S; Dennehy M; Kim H;
    Vaccine; 2018 Nov; 36(48):7430-7437. PubMed ID: 29789241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global equity and timely access: COVID-19 & beyond 23rd DCVMN Annual General Meeting 2022 report.
    Suri RK; Liu C; Marini A
    Vaccine X; 2023 Dec; 15():100353. PubMed ID: 37533681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The art of partnerships for vaccines.
    Pagliusi S; Che Y; Dong S
    Vaccine; 2019 Sep; 37(40):5909-5919. PubMed ID: 31447125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality vaccines for all people: Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand.
    Pagliusi S; Ting CC; Khomvilai S;
    Vaccine; 2016 Jun; 34(31):3562-7. PubMed ID: 26947496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Cernuschi T; Malvolti S; Hall S; Debruyne L; Bak Pedersen H; Rees H; Cooke E
    Vaccine; 2024 Apr; 42 Suppl 1(Suppl 1):S64-S72. PubMed ID: 38103962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better vaccines for healthier life. Part I. Conference report of the DCVMN International 14th Annual General Meeting Hanoi, Vietnam.
    Pagliusi S; Rustan R; Huang W; Nguyen T;
    Vaccine; 2014 Nov; 32(48):6325-9. PubMed ID: 24923636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.
    Eccleston-Turner M; Upton H
    Milbank Q; 2021 Jun; 99(2):426-449. PubMed ID: 33650737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
    So AD; Woo J
    BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Hayman B; Dennehy M
    Vaccine; 2021 Aug; 39(36):5153-5161. PubMed ID: 34362602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines: Shaping global health.
    Pagliusi S; Ting CC; Lobos F;
    Vaccine; 2017 Mar; 35(12):1579-1585. PubMed ID: 28237501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redressing COVID-19 vaccine inequity amidst booster doses: charting a bold path for global health solidarity, together.
    Rackimuthu S; Narain K; Lal A; Nawaz FA; Mohanan P; Essar MY; Charles Ashworth H
    Global Health; 2022 Feb; 18(1):23. PubMed ID: 35193616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two decades of vaccine innovations for global public good: Report of the Developing Countries' Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil.
    Pagliusi S; Dennehy M; Homma A
    Vaccine; 2020 Aug; 38(36):5851-5860. PubMed ID: 32535016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccine capacity: Challenges and mitigation - The DCVMN perspective.
    Hayman B; Suri R; Prasad SD
    Vaccine; 2021 Aug; 39(35):4932-4937. PubMed ID: 34325932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.